reMYND and Novo Nordisk have entered into a license agreement to further develop reMYND’s ReS39 therapeutic treatment for diabetes. This program holds also promise for NASH and the metabolic syndrome.     ReS39 sustains and increases the endogenous insulin production capacity of the pancreas by restoring beta-cell function and insulin signalling in Type 1 and Type 2 diabetes animal models.   Koen De Witte, managing director of reMYND, said,  “Diabetes patients would greatly...